Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
Plain-language summary
This trial is testing CD5-directed CAR-T cell therapy for patients with various types of peripheral T-cell lymphoma (PTCL) whose disease has come back or stopped responding to prior treatment. This is a Phase 1/2 trial, which means researchers are determining the best dose and getting early information about effectiveness. Patients are randomly assigned to different treatment groups. This trial does not currently have sites in the United States. The trial is currently recruiting patients.
Who can join (key eligibility)
- Age 18 Years to 75 Years years
- Lymphoma came back or did not respond to prior treatment
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Autologous CD19/CD22 dual-target CAR-T module (BIOLOGICAL): Biological: Autologous CD19/CD22 dual-target CAR-T module after lymphodepletion with fludarabine/cyclophosphamide. | Autologous CD19/CD20 dual-target CAR-T module (BIOLOGICAL): Biological: Autologous CD19/CD20 dual-target CAR-T module after lymphodepletion with fludarabine/cyclophosphamide. | Autologous BCMA/CD19 dual-target CAR-T module (BIOLOGICAL): Biological: Autologous BCMA/CD19 dual-target CAR-T module after lymphodepletion with fludarabine/cyclophosphamide. | Autologous BCMA/CD38 dual-target CAR-T module (BIOLOGICAL): Biological: Autologous BCMA/CD38 dual-target CAR-T module after lymphodepletion with fludarabine/cyclophosphamide. | Autologous BCMA/GPRC5D dual-target CAR-T (BIOLOGICAL): Biological: Autologous BCMA/GPRC5D dual-target CAR-T module after lymphodepletion with fludarabine/cyclophosphamide | Autologous CD33/CD123 dual-target CAR-T module (BIOLOGICAL): Biological: Autologous CD33/CD123 dual-target CAR-T module (simultaneous or planned sequential paired infusion, module-specific) after lymphodepletion. | Autologous CD33/CLL1 dual-target CAR-T module (BIOLOGICAL): Biological: Autologous CD33/CLL1 dual-target CAR-T module after lymphodepletion with fludarabine/cyclophosphamide. | Autologous CD5/CD7 dual-target CAR-T module (BIOLOGICAL): Biological: Autologous CD5/CD7 dual-target CAR-T module (including sequential paired infusion if needed for manufacturing/safety) after lymphodepletion.
Autologous CD19/CD22 dual-target CAR-T module, Autologous CD19/CD20 dual-target CAR-T module, Autologous BCMA/CD19 dual-target CAR-T module, Autologous BCMA/CD38 dual-target CAR-T module, Autologous BCMA/GPRC5D dual-target CAR-T, Autologous CD33/CD123 dual-target CAR-T module, Autologous CD33/CLL1 dual-target CAR-T module, Autologous CD5/CD7 dual-target CAR-T module
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details